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ABSTRACT
Tumor cell resistance to apoptosis, which is triggered by many anti-tumor 
therapies, remains a major clinical problem. Therefore, development of more efficient 
therapies is a priority to improve cancer prognosis. We have previously shown that a 
cell-permeable peptide derived from the p120 Ras GTPase-activating protein (RasGAP), 
called TAT-RasGAP317-326, bears anti-malignant activities in vitro and in vivo, such as 
inhibition of metastatic progression and tumor cell sensitization to cell death induced 
by various anti-cancer treatments. Recently, we discovered that this RasGAP-derived 
peptide possesses the ability to directly kill some cancer cells. TAT-RasGAP317-326 can 
cause cell death in a manner that can be either partially caspase-dependent or fully 
caspase-independent. Indeed, TAT-RasGAP317-326-induced toxicity was not or only 
partially prevented when apoptosis was inhibited. Moreover, blocking other forms 
of cell death, such as necroptosis, parthanatos, pyroptosis and autophagy did not 
hamper the killing activity of the peptide. The death induced by TAT-RasGAP317-326 
can therefore proceed independently from these modes of death. Our finding has 
potentially interesting clinical relevance because activation of a death pathway that 
is distinct from apoptosis and necroptosis in tumor cells could lead to the generation 
of anti-cancer drugs that target pathways not yet considered for cancer treatment.
INTRODUCTION
Cancer ranks among the leading causes of death 
worldwide [1]; this makes the development of novel 
and improved anti-cancer treatment a priority. Current 
oncological therapeutics aim to activate apoptosis to 
achieve disease control. However, cancer cells can 
adapt and become refractory to therapy by mutating 
and acquiring the ability to resist apoptotic stimuli [2]. 
The ability to evade apoptosis is one of the hallmarks of 
cancer [3]. Resistance leads to cancer cell survival and 
relapse. Consequently, development of treatments able 
to trigger non-apoptotic forms of death in cancer cells is 
of prime interest. There are many ways for mammalian 
cells to die, which could be divided into two main 
categories: accidental cell death (ACD) or regulated 
cell death (RCD) [4-6]. ACD is a form of death that 
is not induced by physiological or pathological insults 
and that does not involve the signaling machinery of 
cells. For example, ACD can result from exposure to 
extreme mechanical or chemical stimuli. In contrast, 
RCD requires genetically encoded molecular signaling 
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pathways and consequently can be modulated by genetic 
or pharmacologic interventions. Regulated forms of 
cell death include the intensively studied apoptosis, 
necroptosis and autophagy but also less known forms 
of death such as pyroptosis and parthanatos. These 
different types of cell death diverge at the level of 
the morphological changes and biochemical features 
triggered by death stimuli [4-6].
TAT-RasGAP317-326, a cell-permeable peptide derived 
from the p120 GTPase-activating protein (RasGAP), bears 
anti-malignant activities, including inhibition of metastatic 
progression and tumor cell sensitization to cell death 
induced by anti-cancer therapies [7-12]. This compound, 
in the initial tumor cell lines tested and at the given doses 
assessed was not found to affect their viability [7]. By 
screening additional tumor cells, however, we discovered 
that some cancer cell lines are directly killed by the 
RasGAP-derived peptide. The aim of the present study 
was to investigate which type of death was activated by 
TAT-RasGAP317-326 in the cells that are directly eliminated 
by the peptide.
RESULTS
TAT-RasGAP317-326 directly kills a subset of 
cancer cells
By screening a variety of cancer cell lines for their 
ability to become more sensitive to genotoxins in the 
presence of TAT-RasGAP317-326, we found 13 tumor cell 
lines that were directly killed by the peptide (Table 1). 
Among these, five are B-cell-derived cell lines (Daudi, 
Namalwa, Raji, Ramos and SKW6.4). To determine if 
non-transformed B cells were affected by the peptide, 
purified B cells (CD19+ cells) from healthy donors were 
tested. Supplementary Figure S1 shows that normal B cells 
were killed by TAT-RasGAP317-326 while peripheral blood 
lymphocytes (PBL) were barely affected. This indicates 
that the RasGAP-derived peptide can be detrimental to a 
fraction of immune circulating cells and this will have to 
be taken into account in case the peptide is therapeutically 
used.
Two of the tumor cells that were efficiently killed 
by the peptide, the Raji Burkitt lymphoma and the 
NB1 neuroblastoma cell lines, were used to investigate 
the manner by which the peptide induced death. 
Supplementary Figure S2 shows that the peptide did not 
alter the proportion of cells in a given cell cycle stage, 
suggesting that cell cycle regulators are not targeted by 
the peptide. When treated with an inactive point mutant of 
the peptide [TAT-RasGAP317-326 (W317A)] [13], or with the 
TAT cell-penetrating peptide alone, viability of Raji and 
NB1 cells was not affected (Figure 1A). This demonstrates 
that the direct killing ability of TAT-RasGAP317-326 is 
not carried solely by the TAT moiety but depends on 
specific RasGAP sequences. TAT-RasGAP317-326 induced 
membrane permeabilization in a dose-dependent manner 
in both Raji and NB1 cells (Supplementary Figure S3A). 
The kinetic of death, induced by the peptide was assessed 
using Annexin-V and 7AAD staining. Annexin-V binds 
to phosphatidylserine (PS) exposed at the cell surface, a 
phenomenon that is generally characteristic of apoptosis. 
The 7AAD dye is plasma membrane impermeable and 
thus only labels cells with compromised cell permeability, 
which is typically seen in necrotic cells. Apoptotic cells 
bind Annexin-V but remain initially 7AAD negative 
[14]. Figure 1B-1C shows that Annexin-V and 7AAD 
positivity occurred concomitantly in Raji and NB1 cells 
when incubated with TAT-RasGAP317-326. In contrast and 
as expected, apoptotic inducers in these cells (e.g. Fas 
ligand (FasL) or etoposide) induced PS exposure before 
membrane impermeability was compromised (Figure 1D). 
Of note, in both Raji and NB1 cells, TAT-RasGAP317-326 
induced a drop in mitochondrial membrane potential 
(Supplementary Figure S3B).
Reactive oxygen species (ROS) production upon 
peptide treatment was investigated. Intracellular hydrogen 
peroxide (H2O2) and cytosolic superoxide (CO2
.-) were not 
augmented by TAT-RasGAP317-326 (Supplementary Figure 
S4A). The sensors for these ROS were functional as 
shown in Jurkat cells treated with APO866, a nicotinamide 
phosphoribosyltransferase inhibitor (Supplementary 
Figure S4B). In contrast to hydrogen peroxide and 
cytosolic superoxide, mitochondrial superoxide (mO2
.-) 
was increased in NB1 and, less markedly, in Raji cells in 
response to TAT-RasGAP317-326 treatment (Supplementary 
Figure S4A). To assess the impact of mitochondrial 
ROS production on the viability of these cells, they were 
incubated with MitoTEMPO, a mitochondria-specific 
ROS scavenger. Supplementary Figure S4C shows that 
MitoTEMPO efficiently reduced TAT-RasGAP317-326-
induced mO2
.- production in NB1 cells and this lowered 
death induced by the peptide. However, in Raji cells, 
MitoTEMPO did neither reduce the level of mO2
.- 
nor TAT-RasGAP317-326-induced death. While it is not 
clear why MitoTEMPO failed to inhibit mitochondrial 
superoxide production in Raji cells, the data obtained in 
NB1 cells indicate that TAT-RasGAP317-326 might kill some 
cells via production of mitochondrial ROS.
As the RasGAP-derived peptide impacted the 
functionality of mitochondria, we determined if it 
modulated cellular ATP levels. As shown in Supplementary 
Figure S4D, the peptide induced a drop in ATP levels 
in Raji and NB1 cells. Intriguingly, this drop started to 
occur before any detectable cell death, suggesting that 
the peptide impacts cellular metabolism before inducing 
membrane permeabilization.
To evaluate the morphological changes involved 
in TAT-RasGAP317-326-induced cell death, we performed 
ultrastructural analyses in Raji and NB1 cells using 
electron microcopy (Figures 2 and 3). To have a 
comparison with apoptosis, we also treated Raji cells 
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Table 1: Cell lines tested for their sensitivity to TAT-RasGAP317-326.
TAT-RasGAP317-326 (µM)
Cell line 10 20 40 60 80 Ref
293T (embryonic kidney) ND - - ND + Unpublished
501Mel (melanoma) ND - - ND ND Unpublished
A375 (melanoma) - - ++ ++ ND Unpublished
A673 (Ewing sarcoma) - ND ND ND ND [12]
CCRF-CEM (acute T cell 
leukemia) - ND ND ND ND [12]
Daudi (Burkitt lymphoma) - ++ ++ ND ND Unpublished
EW-11 (Ewing sarcoma) - ND ND ND ND [12]
H1299 (non-small cell lung 
carcinoma) ND - ND ND ND [46]
HaCat (non-tumor keratinocyte) ND - ND ND ND [7]
HCT116 (colorectal carcinoma) ND - ND ND ND [7]
HeLa (cervical cancer) - - + ND ++ [7] / Unpublished
H-meso1 (lung mesothelioma) ND - ND ND ND [7]
HUVECC (non-tumor endothelial 
cells) ND - ND ND ND [7]
IGr37 (melanoma) ND - - ND ND Unpublished
IPC298 (melanoma) ND - - ND ND Unpublished
Jurkat (acute T cell leukemia) - - ND ND ND Unpublished
LAN-1 (neuroblastoma) - ND ND ND ND [12]
Lymphocytes (human PBL) - - + ND + [12] / Unpublished
MCF-7 (breast cancer) ND - ND ND ND [7]
MEF (mouse embryo fibroblast) ND - ND ND ND [44]
MelJuso (melanoma) ND - - ND ND Unpublished
MO7e (acute myeloid leukemia) - ND ND ND ND [12]
Namalwa (Burkitt lymphoma) - - - + ++ Unpublished
NB1 (neuroblastoma) - ++ ++ ++ ++ [12]/This study
PC3 (prostate cancer) ND - ND ND ND Unpublished
Raji (Burkitt lymphoma) - ++ ++ ++ ++ This study
Ramos (Burkitt lymphoma) - + ++ ND ++ Unpublished
RPMI-8226 (myeloma) - - ND ND ND Unpublished
SAOS (osteosarcoma) ND - ND ND ND [46]
SkMel30 (melanoma) ND - - ND ND Unpublished
SK-N-Be(2)c (neuroblastoma) - ND ND ND ND [12]
SKW6.4 (transformed 
B-lymphoblastoid) - ++ ++ ++ ++ Unpublished
(Continued )
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with FasL, a well-known apoptotic inducer (Figure 2). 
FasL treatment induced apoptotic cell death with classical 
morphological criteria including nuclear and cytoplasmic 
condensation, chromatin condensation throughout the 
nucleus (pyknosis), nuclear fragmentation, and minimal 
alterations of organelles (including mitochondria). TAT-
RasGAP317-326-treated Raji cells displayed different 
morphological features than those seen in FasL-treated 
cells (Figure 2). At first, slight and heterogeneous 
chromatin condensation without nuclear fragmentation, 
shrinkage of the cytoplasm and accumulation of 
cytoplasmic materials around the nucleus were observed. 
Organelles aggregated in distinct portions of the cytoplasm 
whereas some cytoplasmic areas seemed to be devoid 
of organelles. Organelles displayed a relatively good 
preservation but some mitochondria showed condensed 
features. Then, at later stages, Raji cells displayed a 
necrotic-like phenotype such as huge organelle swelling 
and loss of plasma membrane integrity. The inactive 
TAT-RasGAP317-326 (W317A) mutant did not alter the 
ultrastructural morphology of Raji cells.
Whereas TAT-RasGAP317-326-induced Raji cell 
death displayed a non-canonical morphological 
phenotype, TAT-RasGAP317-326-induced NB1 cell death 
showed some morphological features of apoptosis 
including chromatin condensation, nuclear fragmentation 
and condensed mitochondria at early stage and then 
secondary necrosis morphological features at later stage 
(Figure 3). Morphological features in TAT-RasGAP317-326-
induced NB1 cell death are therefore relatively similar 
to those observed when NB1 cells were exposed to the 
pro-apoptotic drug etoposide. However, clear differences 
were detected at the ultrastructural level between TAT-
RasGAP317-326- and etoposide-treated NB1 cells. For 
example, the peptide never induced pyknosis in NB1 
cells while etoposide almost always did so. Moreover, 
cytoplasmic materials often accumulated close to the 
nucleus in response to TAT-RasGAP317-326, while this was 
rarely the case when cells were incubated with etoposide. 
As seen in Raji cells, the inactive TAT-RasGAP317-326 
(W317A) mutant had no effect on the ultrastructure of 
NB1 cells.
The data shown in Figures 2 and 3 indicate that TAT-
RasGAP317-326 is inducing a form of death that is sharing 
some characteristics with apoptosis, at least in some cell 
lines, but which does not seem to be strictly equivalent to 
this mode of death. We therefore aimed to determine if 
other types of cell death were triggered by the RasGAP-
derived peptide.
Apoptosis inhibition does not protect against 
TAT-RasGAP317-326-induced cell death in Raji 
cells and only partially in NB1 cells
TAT-RasGAP317-326 induced caspase-3 activation 
and PARP1 cleavage in both Raji and NB1 cells (Figure 
4A), indicating that the peptide can trigger an apoptotic 
program. However, inhibition of caspase activity with 
the pan-caspase Z-VD-fmk inhibitor [15, 16] (Figure 
4A), while efficiently blocking apoptosis triggered 
by FasL, had no effect on death induced by TAT-
RasGAP317-326 in Raji cells (Figure 4B). In NB1 cells, 
however, a partial protection was observed (Figure 4B). 
Intrinsic mitochondrial apoptosis is characterized by the 
release of cytochrome c into the cytosol, which depends 
on the pore forming proteins Bax and Bak. Unlike tBid, 
TAT-RasGAP317-326 did not induce cytochrome c release 
from isolated mitochondria (Supplementary Figure S5), 
suggesting no direct action at the mitochondria level. 
The activity of Bax and Bak can be inhibited by over-
expression of anti-apoptotic Bcl-2 family members, 
such as Bcl-XL [17, 18]. Bcl-XL over expression (Figure 
4C) partially prevented TAT-RasGAP317-326-induced 
apoptosis in NB1 cells (Figure 4D). In Raji cells, 
etoposide, even at high doses, only induced a slight 
increase in apoptosis, most probably because Raji cells 
express high basal level of Bcl-2 [19]. However, Bcl-
XL overexpression did not protect Raji cells against 
TAT-RasGAP317-326 (µM)
Cell line 10 20 40 60 80 Ref
TC252 (Ewing sarcoma) - ND ND ND ND [12]
THP-1 (acute myeloid leukemia) - - ++ ++ ++ [12] / Unpublished
U2OS (osteosacroma) - - - - - [7] / Unpublished
Vero (monkey kidney) - - - ND + Unpublished
WM1366 (melanoma) ND + ++ ND ++ Unpublished
WM3248 (melanoma) ND + ++ ND ++ Unpublished
ND: not determined. -: not killed. +: < 20% killed. ++: > 20% killed.
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TAT-RasGAP317-326-induced death (Figure 4D). Similar 
results were obtained when Bax and Bak expression 
were removed by gene disruption using the CRISPR/
Cas9 technology (Figure 4E-4F). Combining Bcl-XL 
overexpression and Z-VD-fmk treatment did not induce 
a stronger inhibition of TAT-RasGAP317-326-induced 
death in NB1 cells as compared to individual inhibitor 
applications (Figure 4G).
Figure 1: TAT-RasGAP317-326 directly kills Raji and NB1 cells A. Raji cells and NB1 cells were treated for 16 and 24 hours, 
respectively, with 0, 20 and 40 µM TAT-RasGAP317-326, TAT or TAT-RasGAP317-326(W317A). Cell death, corresponding to the percentage of 
propidium iodide (PI)-positive cells, was determined by flow cytometry. Results correspond to the mean +/- 95% confidence interval (CI) 
of 3 independent experiments. B. Raji and NB1 cells were treated with 20 µM and 40 µM TAT-RasGAP317-326, respectively, for the indicated 
periods of time. Phosphatidylserine exposure and plasma membrane permeabilization were then analyzed by flow cytometry using Annexin-V 
and 7AAD staining, respectively. C. Double stain analysis of 7AAD- and Annexin-V positive cells in Raji and NB1 cells after the indicated 
periods of time of TAT-RasGAP317-326 treatment. D. Raji and NB1 cells were treated with 150 ng/mL FasL for 16 hours and 10 µg/mL etoposide 
for 9 hours, respectively. Cell death was analyzed as in panel B. The results correspond to the mean +/- 95% CI of 3 independent experiments.
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Figure 2: Ultrastructural analysis of TAT-RasGAP317-326-induced cell death in Raji cells. Representative electron micrographs 
showing the morphological ultrastructural features in Raji cells left untreated (Ctrl) or incubated with 20 μM TAT-RasGAP317-326 (W317) (24 
hours), 20 μM TAT-RasGAP317-326 (24 hours) or with 150 ng/mL FasL (16 hours). Scale bars: 5 µm. n: nucleus; m: mitochondria.
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Figure 3: Ultrastructural analysis of TAT-RasGAP317-326-induced cell death in NB1 cells. Representative electron micrographs 
showing the morphological ultrastructural features in NB1 cells in control condition (Ctrl) or after 40 μM TAT-RasGAP317-326 (w317A) (24 
hours), 40 μM TAT-RasGAP317-326 (24 hours) or 10 μg/mL etoposide (8 hours) treatments. Scale bar: 5 µm. n: nucleus; m: mitochondria.
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Figure 4: Inhibition of apoptosis does not prevent TAT-RasGAP317-326-induced cell death. A. Raji cells and NB1 cells were 
pre-incubated or not 1 hour with 10 µM of the pan-caspase inhibitor Z-VD-fmk. Raji cells were then treated with 20 µM TAT-RasGAP317-326 
for 16 hours and NB1 cells with 40 µM TAT-RasGAP317-326 for 24 hours. Cells were lysed and cleavage of PARP and caspase-3 analyzed 
by Western blotting. B. Raji and NB1 cells were pre-incubated or not 1 hour with 10 µM of the pan-caspase inhibitor Z-VD-fmk. Raji 
cells were then treated with 20 µM TAT-RasGAP317-326 (P20) and 150 ng/mL Fas-ligand (FasL) for 16 hours. NB1 cells were treated with 
40 µM TAT-RasGAP317-326 (P40) and 30 µM 4-HC, the active form of cyclophosphamide, for 24 hours. Cell death (corresponding to the % 
of Annexin-V positive cells) was determined by FACS. Results correspond to the mean +/- 95% CI of 3 independent experiments. C. Raji 
and NB1 cells were infected with empty viruses or viruses encoding Bcl-XL. Bcl-XL expression levels were assessed by Western blotting. 
D. Raji cells overexpressing or not Bcl-XL were treated with 20 μM TAT-RasGAP317-326 and 250 μM etoposide (eto) for 16 hours. NB1 cells 
overexpressing or not Bcl-XL were treated with 40 μM TAT-RasGAP317-326 and 50 μM etoposide for 24 hours. Cell death (corresponding 
to the % of 7AAD positive cells) was determined by FACS. The results correspond to the mean +/- 95% CI of at least three independent 
experiments. E. Bax and Bak were disrupted in Raji and NB1 cells using the CRISPR/Cas9 technology. Loss of expression was confirmed 
by Western blotting. F. Wild-type and Bax/Bak double-knock-out Raji and NB1 cells were treated with 20 µM TAT-RasGAP317-326 for 16 
hours and 40 µM TAT-RasGAP317-326 for 24 hours, respectively. Cell death (corresponding to the % of PI-positive cells) was determined 
by FACS. Results correspond to the mean +/- 95% CI of 3 independent experiments. G. NB1 cells overexpressing or not Bcl-XL were pre-
incubated or not 1 hour with 10 μM of the pan-caspase inhibitor Z-VD-fmk and then treated with 40 μM TAT-RasGAP317-326. After 24 hours 
incubation, cell death (corresponding to the % of 7AAD-positive cells) was determined by FACS.
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TAT-RasGAP317-326 does not trigger necroptosis
As apoptosis was not, or only partially, involved in 
the death induced by TAT-RasGAP317-326, we investigated 
whether other forms of death could be involved. 
Necroptosis, also called programmed necrosis, is a form 
of cell death that differs from apoptosis at morphological 
and signaling levels [20, 21]. It is characterized by cell 
rounding, gain in cell volume, organelle swelling and 
plasma membrane rupture. Necroptosis requires receptor-
interacting protein (RIP) 1 and 3. The downstream target 
of the complex formed by RIP1/RIP3 was identified 
as mixed lineage kinase domain-like protein (MLKL) 
[22, 23]. Activation of MLKL leads to its translocation 
from the cytosol to plasma and intracellular membranes, 
and subsequent loss of membrane integrity [24]. In 
cells such as the HT29 colorectal adenocarcinoma, 
necroptosis can be triggered by tumor necrosis factor 
alpha (TNF-α) stimulation when caspases and translation 
are inhibited [25]. We were however unable to induce 
Raji and NB1 necroptosis using this protocol. This 
could be the consequence of a low MLKL expression 
(Figure 5A). To assess the involvement of necroptosis in 
TAT-RasGAP317-326-induced death, Raji cells were treated 
with necrosulfonamide (NSA), an MLKL inhibitor [23]. 
NSA efficiently prevented necroptosis in HT29 cells 
(Figure 5B) but had no effect on the death provoked by 
the RasGAP-derived peptide (Figure 5C). One could 
argue that NSA might not be efficient in Raji cells, even 
at concentrations shown to be efficient in sensitive cell 
lines such as HT29. We therefore knocked out MLKL 
in Raji and NB1 cells as another approach to prevent 
necroptosis. Because endogenous levels of MLKL in these 
cells were low and could not be detected in Raji and NB1 
cells (Figure 5A), the targeted DNA region by the Cas9 
endonuclease was sequenced. Figure 5D shows that both 
alleles of Raji clones #2 and #6 and NB1 clones #B3 and 
#A6 were disrupted, engendering frameshift mutations. 
These MLKL disrupted clones were then treated with the 
TAT-RasGAP317-326 peptide but this did not prevent cell 
death (Figure 5E). Collectively, these data demonstrate 
that TAT-RasGAP317-326 does not require the molecular 
machinery of necroptosis to kill Raji and NB1 cells.
TAT-RasGAP317-326 does not trigger pyroptosis
We next examined the implication of pyroptosis. 
This form of programmed cell death is stimulated by 
microbial and viral infections but also by stroke and cancer 
[26]. Morphological features displayed by pyroptotic 
cells are common with apoptosis and/or necrosis [26, 27]. 
Defined as a caspase-1-dependent cell death, pyroptosis 
results in the production of inflammatory cytokines such 
as interleukin-1β (IL-1β) and IL-18 and ends up in cell 
lysis. To determine whether pyroptosis is a type of cell 
death induced by TAT-RasGAP317-326, Raji and NB1 cells 
lacking caspase-1 were generated. Loss of caspase-1 
expression was confirmed in different clones by Western 
blotting (Figure 6A). The ability of the peptide to cause 
cell death was not abrogated in caspase-1 knock-out Raji 
and NB1 cells (Figure 6B). This is in line with the caspase 
inhibition results shown above (Figure 4B) as Z-VD-
fmk is also expected to prevent caspase-1 activity [16]. 
Altogether, this indicates that the RasGAP-derived peptide 
does not elicit pyroptosis.
TAT-RasGAP317-326 does not trigger parthanatos
Parthanatos is a cell death mode that is initiated 
by over-activation of poly (ADP-ribose)-polymerase 
1 (PARP1). Under physiological conditions, PARP1 is 
involved in DNA repair. To maintain genomic homeostasis, 
PARP1 detects single strand DNA breaks, uses NAD+ to 
synthetize poly (ADP-ribose) (PAR) and attaches PAR on 
itself and other target proteins [28, 29]. This leads to the 
recruitment of critical proteins for DNA repair [30, 31]. 
Hyperactivation of PARP1 contributes to NAD+ and ATP 
depletion and translocation of apoptosis-inducing factor 
(AIF) from the mitochondria to the nucleus [32-34]. To 
investigate if TAT-RasGAP317-326 triggers parthanatos, 
PARP1 knock-out cells were generated. Loss of PARP1 
expression was controlled by Western blotting (Figure 
6C). Figure 6D shows that in the absence of PARP1, Raji 
and NB1 cells are still killed by the peptide. Hence, the 
peptide does not trigger parthanatos.
Autophagy and TAT-RasGAP317-326-induced 
death
Autophagy is a process of self-degradation. During 
starvation, it allows cells to maintain energy levels via 
the degradation and recycling of cellular cytoplasmic 
constituents, allowing cell survival. Autophagosome 
formation involves the lipidation of the LC3 protein [35]. 
This pro-survival function of autophagy is well accepted 
[36, 37]. Autophagy may in some conditions trigger cell 
death [38]. To test if the peptide modulates autophagy, 
the autophagic marker lipidatino of LC3 was examined 
by Western blotting. Figure 7A shows that conversion of 
the LC3-I unlipidated form to the LC3-II lipidated form 
is similar in untreated cells and in cells treated with TAT-
RasGAP317-326. To rule out the involvement of autophagy 
in TAT-RasGAP317-326-triggered death, two autophagic 
genes, ATG5 and ATG6, were disrupted (Figures 7B and 
7D). Disruption of ATG5 fully prevented autophagy in 
Raji cells, as assessed by the absence of LC3 lipidation 
in serum deprivated conditions (Figure 7F). Moreover, 
autophagy induced by serum starvation fully prevented 
in cells lacking ATG6 (Figure 7F). However, the absence 
of ATG5 and ATG6 did not prevent TAT-RasGAP317-326-
induced cell death in Raji and NB1 cells (Figures 7C 
and 7E), suggesting that autophagy plays no role in TAT-
RasGAP317-326-mediated death.
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Figure 5: TAT-RasGAP317-326-induced cell death does not require the necroptosis machinery. A. Expression of MLKL 
in wild-type HT29 cells, Raji cells and NB1 cells assessed by Western blotting. B. HT29 cells were pretreated for 1 hour with 10 μM 
necrosulfonamide (NSA) and necroptosis was induced by the addition of 30 ng/ml TNF-α (T), 2 μg/ml cycloheximide (C) and 10 μM 
Z-VD-fmk (Z). After 24 hours, cell death was determined by FACS after staining with PI. C. Raji cells were pretreated for 1 hour with 10 
μM NSA before the addition of 20 μM TAT-RasGAP317-326 (P). After 16 hours incubation, cell death (corresponding to the % of PI-positive 
cells) was determined by FACS. The results correspond to the mean +/- 95% CI of three independent experiments. D. DNA sequences of 
wild-type MLKL gene and MLKL alleles of clones 2 and 8 and clones B3 and A6 of Raji cells and NB1 cells, respectively. Differences 
with the wild-type MLKL sequence are highlighted in bold. The sgRNAs directed against MLKL are highlighted in grey. E. Wild-type and 
MLKL disrupted Raji and NB1 cells were treated for 16 and 24 hours, respectively. Cell death (corresponding to the % of PI-positive cells) 
was measured by FACS. The results correspond to the mean +/- 95% CI of minimum three independent experiments.
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It is possible that the peptide triggers cell death 
via the activation of several pathways in parallel. We 
therefore investigated the effect of multiple cell death 
inhibition on TAT-RasGAP317-326 toxicity. Figure 7G 
shows that inhibition of apoptosis and necroptosis 
in autophagy-deficient Raji and NB1 cells did not 
protect against the cytotoxic effect of the peptide. 
Taken together, these results indicate that none of the 
“classical” death pathways mediate the killing activity 
of TAT-RasGAP317-326.
Figure 6: TAT-RasGAP317-326-induced cell death is caspase-1- and PARP1-independent. A. Caspase-1 was disrupted in Raji 
and NB1 cells using the CRISPR/Cas9 technology. Loss of expression was confirmed by Western blotting. B. Wild-type and caspase-1 
knock-out Raji cells were treated or not with 20 µM TAT-RasGAP317-326 (P) for 16 hours. Wild-type and caspase-1 knock-out NB1 cells were 
treated or not with 40 µM TAT-RasGAP317-326 (P) for 24 hours. Cell death was then assessed by flow cytometry after PI staining. Results 
correspond to the mean +/- 95% CI of 3 independent experiments. C. PARP1 was disrupted in wild-type Raji and NB1 cells using CRISPR/
Cas9 technology. Loss of expression was confirmed by Western blotting. D. Wild-type and PARP1 knock-out Raji cells were treated or not 
with 20 µM TAT-RasGAP317-326 (P) for 16 hours. NB1 cells were treated or not with 40 µM TAT-RasGAP317-326 (P) for 24 hours. Cell death 
was then assessed by flow cytometry after PI staining. Results correspond to the mean +/- 95% CI of 3 independent experiments.
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Figure 7: Autophagy is not involved in TAT-RasGAP317-326-induced cell death. A. Raji cells were treated during 16 hours 
with 20 μM TAT-RasGAP317-326 (P) or not (N/T) and LC3 expression was analyzed by Western blotting. NB1 cells were treated during 
the indicated periods of time with 40 μM TAT-RasGAP317-326 and LC3 expression was analyzed by Western blotting. B. and D. ATG5 and 
ATG6 were individually disrupted in Raji and NB1 cells using the CRISPR/Cas9 technology. Loss of expression was confirmed by Western 
blotting. C. Wild-type and ATG5 knock-out Raji cells were treated or not with 20 μM TAT-RasGAP317-326 (P) for 16 hours. Wild-type and 
ATG5 knock-out NB1 cells were treated or not with 40 µM TAT-RasGAP317-326 (P) for 24 hours. Cell death was then assessed by flow 
cytometry after PI staining. Results correspond to the mean +/- 95% CI of 3 independent experiments. E. Wild-type and ATG6 knock-
out Raji and NB1 cells were treated as described in panel D. Cell death was then assessed by flow cytometry after PI staining. Results 
correspond to the mean +/- 95% CI of 3 independent experiments. F. Wild-type, ATG5 knock-out and ATG6 knock-out Raji cells were 
cultured for 48 hours in presence or absence of serum. LC3 conversion was analyzed by Western blotting. G. Wild-type, ATG5 knock-out 
and ATG6 knock-out Raji cells were pretreated or not with 10 µM Z-VD-fmk and 10 μM necrosulfonamide (NSA) for 1 hour and then 
treated or not with 20 μM TAT-RasGAP317-326 (P) for 16 hours. Wild-type, ATG5 knock-out and ATG6 knock-out NB1 cells were pretreated 
or not with 10 µM Z-VD-fmk and 10 μM necrosulfonamide (NSA) for 1 hour and then treated or not with 40 µM TAT-RasGAP317-326 (P) 
for 24 hours. Cell death was then assessed by flow cytometry after PI staining. Results correspond to the mean +/- 95% CI of 3 independent 
experiments.
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DISCUSSION
Apoptosis had been the most intensively studied 
mode of regulated cell death for years. Thus, apoptotic 
inducers were and are largely used in the clinic as cancer 
therapies. However, tumor cell resistance to apoptosis, 
leading to cancer progression, is currently a major clinical 
problem. Some strategies could overcome this problem. 
For example, restoring the sensitivity of cancer cells to 
apoptosis might improve the efficacy of anti-tumor drugs. 
Another possibility would be to trigger alternate modes of 
death to which cancer cells are not resistant. The results 
presented here indicate that the TAT-RasGAP317-326 peptide 
has the capacity to kill some tumor cells in a manner 
distinct from the known characterized forms of death.
Our data show that necroptosis, autophagy, 
parthanatos and pyroptosis are neither activated nor 
involved in the toxicity induced by TAT-RasGAP317-326. 
In contrast, the apoptotic pathway is efficiently 
stimulated by the peptide. However, inhibiting 
apoptosis, either pharmacologically or genetically, 
did not (Raji cells), or only partially (NB1 cells), 
prevent TAT-RasGAP317-326 cytotoxicity. Hence, TAT-
RasGAP317-326 has the potential to activate apoptosis and 
another form of cell death that is distinct from the above 
mentioned death pathways. The ability of triggering 
multiple forms of death has been reported for other 
compounds. Indeed, shikonin and cisplatin, depending 
on the concentrations used, stimulate either apoptosis 
or necroptosis/necrosis [39, 40]. Another example is 
the lipophilic mitochondria-targeted F16 compound that 
was shown to elicit death via apoptosis [41]. However, 
Bcl-2 overexpression did not block the capacity of F16 
to trigger a necrotic cell death, demonstrating that one 
compound can have a dual ability to kill through both 
apoptosis and necrosis.
Our results clearly indicate that TAT-RasGAP317-326 
has the potential to stimulate both apoptosis and an 
alternative form of death in tumor cells of various origins. 
However, it is currently not known whether these two 
forms of death are activated independently or whether the 
triggering event leading to the alternative form of death 
has the capacity to also stimulate apoptosis.
In Raji cells, the sensitivity to the alternative 
form of death stimulated by TAT-RasGAP317-326 is 
seemingly high and the apoptotic pathway can be blocked 
without affecting the overall death response. In NB1 
cells, activation of the alternate form of death appears 
suboptimal and efficient killing requires concomitant 
activation of apoptosis. Consequently, it seems that there 
is a continuum of sensitivities among cancer cell lines to 
the direct killing action of TAT-RasGAP317-326.
Only a fraction of the tested cell lines were found 
to be sensitive to the killing activity of the peptide. 
To assess if those cells share common biological 
features that were not present in the resistant cell 
lines, we performed mutational and transcriptomics 
bioinformatical analyses on six sensitive and 
six resistant cell lines (subjected to 40 µM TAT-
RasGAP317-326). Supplementary Figure S6A lists the 6 
genes with the strongest differential mutational status 
between resistant and sensitive cell lines. Even in these 
genes, there was no strict association between the 
mutation status and the sensitivity of the cell lines to 
the peptide. It is unlikely that these genes, individually 
at least, drive the peptide sensitivity of a cell line. 
In agreement with this is the absence of correlation 
between their expression and the sensitivity of a cell 
line to be killed by the peptide (Supplementary Figure 
S6B). Moreover, there is no statistical support for a 
difference in the overall mutational rate of these cell 
lines (Supplementary Figures S6C-S6D). Gene profiling 
analysis revealed that cell lines cluster according 
to their origin rather than their sensitivity to TAT-
RasGAP317-326 (Supplementary Figure S6E). We finally 
performed a differential expression analysis to find 
whether the expression of certain genes was specifically 
associated with TAT-RasGAP317-326 sensitivity but failed 
to detect any (Supplementary Figure S6F). These 
results suggest that neither mutation nor transcriptional 
regulation are involved in the regulation of TAT-
RasGAP317-326 sensitivity. However, we should take into 
account that the cell lines were not always tested in 
identical experimental conditions (e.g. different culture 
media used for the experimentation). Moreover, as the 
peptide requires entry into cells via the HIV-TAT48-57 
portion, it is also possible that variations in peptide 
intake could explain some of the differences in the 
sensitivity observed between the cell lines.
At present, we cannot rule out the possibility that 
the alternate form of death triggered by the peptide is a 
form of necrosis. One hypothesis that we cannot dismiss 
is that TAT-RasGAP317-326 enters cells and then once 
in the cytoplasm alters, directly or indirectly, plasma 
membrane integrity by interacting with specific molecules 
that are enriched in the inner leaflet of the membrane. 
This mode of action has been reported for defensin 
NaD1, a host defense peptide [42]. NaD1 was shown to 
enter mammalian cells and bind to phosphatidylinositol 
4,5-bisphosphate (PIP2), leading to rapid membrane 
destabilization and permeabilization. As highlighted in 
this example, cell death induced by a peptide may not, or 
not only, depend on protein binding but also on specific 
membrane lipid interaction.
To conclude, our finding could potentially have 
interesting clinical relevance since current anti-cancer 
therapies are mostly based on drugs that induce tumor 
cell apoptosis. Consequently, determining that a 
peptide is able to induce a distinct form of death in 
tumor cells could lead to the generation of innovative 
anti-cancer drugs that complement or be combined 
with existing ones.
Oncotarget14www.impactjournals.com/oncotarget
MATERIALS AND METHODS
Cell lines
All cell lines were cultured in 5% CO2 at 37 °C. 
293T, 501Mel, PC3, HT29, U2OS and Vero were cultured 
in DMEM (Invitrogen, ref. no. 61965) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS; 
Invitrogen, ref. no. 10270-106). Raji, A375, Daudi, HeLa, 
IGr37, IPC298, Jurkat, MelJuso, Namalwa, Ramos, 
RPMI-8226, SKMel30, SKW6.4, THP-1, WM1366 
and WM3248 were cultured in RPMI (Invitrogen, ref. 
no. 61870) supplemented with 10% FBS. The NB1 
neuroblastoma cells were maintained in neural basic 
medium composed of DMEM/F12 (Invitrogen, ref. no. 
31331-028) supplemented with 2% B27 serum-free 
supplement (Invitrogen, ref. no. 17504044), 20 ng/ml 
human recombinant basic fibroblast growth factor (bFGF) 
(Peprotech, ref. no. 100-18B) and 20 ng/ml human 
recombinant epidermal growth factor (EGF) (Peprotech, 
ref. no. AF-100-15). Human peripheral blood lymphocytes 
(PBLs) were isolated by density centrifugation over 
a Ficoll-Paque gradient (Lymphoprep; Stemcell 
Technologies) from buffy coats of healthy human donors, 
obtained from the state of Vaud blood transfusion service. 
The donors gave written consent for potential use of their 
blood for medical research. B cells present in PBLs were 
positively stained with mouse FITC-labelled anti-CD19 
antibody for 30 min at 4°C before flow cytometry analysis.
Chemicals
TNFα and the protease inhibitor tablets were from 
Roche (ref. no. 11088939001 and 4693132001, respectively). 
Cycloheximide and etoposide were from Sigma (ref. no. 
C7698 and E1383 respectively). Necrosulfonamide was from 
Tocris bioscience (ref. no. 5025). The pan-caspase inhibitor 
Z-VD-fmk was a kind gift from Maxim Pharmaceuticals. 
Hexameric Fas ligand, resulting from the aggregation of 6 
fusion proteins between Fas ligand and the Fc portion of 
IgG1 [43], was provided by Pascal Schneider (University of 
Lausanne). Puromycin was from Life technologies (ref. no. 
A11138-02) and 4-hydroperoxycyclophosphamide (4-HC) 
was from Niomech, (ref. no. D-18864).
Peptides
TAT and TAT-RasGAP317–326 are retro-inverso 
peptides (i.e. synthesized with D-amino acids in the 
opposite direction compared to the natural sequence). The 
TAT moiety corresponds to amino acids 48–57 of the HIV 
TAT protein (RRRQRRKKRG) and the RasGAP317–326 
moiety corresponds to amino acids 317–326 of the human 
RasGAP protein (DTRLNTVWMW). These two moieties 
are separated by two glycine linker residues in the 
TAT-Ras-GAP317–326 peptide. TAT-RasGAP317-326(W317A) 
has the tryptophan at position 317 mutated into an alanine. 
The peptides were synthesized at the department of 
biochemistry, University of Lausanne, Switzerland, using 
FMOC technology, purified by HPLC and tested by mass 
spectrometry.
Cell death measurement
Cell death was measured with an Annexin-V-FITC 
/ 7AAD kit (Beckman Coulter, ref. no. IM3614) or with 
propidium iodide (PI) (Sigma, ref. no. 81845) and used 
according to the manufacturer’s instructions. Cells were 
scanned using a Beckman Coulter FC500 flow cytometer 
and data were analyzed with the Kaluza Version 1.3 
software (Beckman Coulter).
Cell cycle analysis
Cells were collected, washed once in PBS and 
fixed in 70 % ethanol at 4°C for 2 hours and then washed 
twice with PBS. DNA was stained with PI solution (10 
μg/mL PI, 150 μg/mL RNase A in water) at 37°C for 30 
minutes. Samples were analyzed by flow cytometry using 
a Beckman Coulter FC500 flow cytometer.
TMRM staining
Cells were collected, washed once in PBS and 
stained with 100 µL of 150 nM tetramethylrhodamine 
methyl ester (TMRM) solution by incubating during 
20 min at 37°C. 500 µL of PBS were added and then 
transferred to a sample tube which was analyzed by 
flow cytometry using a Beckman Coulter FC500 flow 
cytometer.
Mitochondria isolation and cytochrome c release
Cells were harvested in PBS and centrifuged 
10 min at 1,000xg. Cells were then resuspended in 
isotonic mitochondrial buffer (MB) (10 mM HEPES pH 
7.4, 210 mM mannitol, 70 mM sucrose, 1 mM EDTA 
supplemented with one tablet of protease inhibitor 
cocktail per 50 mL), broken by five passages through a 
25G1 0.5- by 2.5-mm needle fitted on a 2 mL syringe 
and centrifuged at 1,500xg for 5 min. This procedure 
was repeated twice and supernatants from each step were 
pooled and centrifuged 5 min at 1,500xg. Supernatant 
was collected, centrifuged 5 min at 2,000xg and further 
centrifuged 10 min at 9,000xg. Pellet was resuspended 
in MB (100 µL), centrifuged 10 min at 7,000xg and 
the pellet, representing the mitochondrial fraction, was 
finally resuspended in a volume of 100 µL of MB. 40 µg 
of mitochondria were incubated in KCl buffer (10 mM 
HEPES pH 7.4; 125 mM KCl; 0.5 mM EGTA; 4 mM 
MgCl2; 5 mM KH2PO4) and left untreated or treated with 
20 µM TAT-RasGAP317–326, 20 µM TAT-RasGAP317–326 
(W317A) or 40 nM tBid for 30 min at 37°C. Samples 
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were then centrifuged 5 min at 16,000xg and supernatant 
and pellet analyzed by Western blotting for the presence 
of cytochrome c.
Antibodies
The rabbit anti-Bcl-XL, the rabbit anti-caspase-3, 
the rabbit anti-LC3, the mouse anti-PARP1, the rabbit 
anti-actin antibodies were from Cell Signaling (ref. no. 
2764, 9662, 2775, 9546, 4970 respectively). The rabbit 
anti-ATG6, the rabbit anti-total Bax and the rabbit 
anti-total Bak were from Santa Cruz Biotechnology 
(ref. no. sc-11427, sc-493 and sc-832 respectively). 
The mouse anti-caspase-1 was from Adipogen (ref. 
no. AG-20B-0048). The rabbit anti-ATG5 was from 
Abcam (ref. no. ab108327). The rat anti-MLKL was 
from Merck Millipore (ref. no. MABC604). The mouse 
FITC-labelled anti-CD19 was from Beckman Coulter 
(ref. no. A07768).
Detection of cellular and mitochondrial ROS
Intracellular levels of cytosolic and mitochondrial 
superoxide as well as H2O2 production were determined 
by flow cytometry using live-cell permeant-specific 
fluorogenic probes, dihydroethidium (DHE; Marker 
Gene Technologies Inc, ref. no MGT-M1241-M010), 
MitoSOX (Molecular Probes, ref. no M36008) and 
6-carboxy-20,70-dichlorodihydrofluorescein diacetate 
(carboxy-H2DCFDA; Molecular Probes, ref. no C-400), 
respectively. DHE is oxidized to red fluorescent ethidium 
by cytosolic superoxide, MitoSOX is selectively 
targeted to mitochondria, where it is oxidized by 
superoxide and exhibits red fluorescence and carboxy-
H2DCFDA becomes green-fluorescent when oxidized 
with intracellular H2O2. After drug treatment, cells were 
harvested and transferred to flow cytometry tubes and 
incubated with 5 µM of specific probe at 37 oC for 30 min. 
Cells were washed twice with PBS, resuspended in 500 µL 
PBS and, for visualization of the intracellular fluorescence, 
probes were excited at 488 nm and fluorescence emission 
were analyzed by flow cytometry.
Determination of intracellular ATP content
Intracellular ATP content was measured with 
the ATP determination kit (Molecular Probes, ref. no 
A22066) according to manufacturer’s instructions. 
Briefly, after drug treatment, cells were collected, 
washed twice in PBS, resuspended in 100 µL lysis buffer 
(NaHCO3 20 mM + Na2CO3 100 mM) and kept at -80°C 
for at least 4h. Cell lysates and ATP standards (10 µL) 
were mixed with standard reaction solution (90 µL) and 
luminescence was determined using an automatized 
bioluminometer (Promega Glomax 96 microplate 
luminometer). ATP level for each sample was normalized 
to protein content.
Plasmids
The lentiviral vector lentiCRISPRv2 [44] was 
obtained from Addgene (#868, Addgene, ref. no. 
52961). The pMD2.G plasmid (#554, Addgene, ref. no. 
12259) encodes the envelope of lentivirus. The psPAX2 
plasmid (#842, Addgene, ref. no. 12260) encodes the 
packaging system. The hBclXL.LEGO-iG2 plasmid 
(#863) was constructed by subcloning the 771 bp EcoRI 
fragment from hBcl-XL. dn3 (#274) into LeGO-iG2 
(#807; Addgene: plasmid 27341).
Lentivirus production
Recombinant lentiviruses hBclXL.LEGO-iG2 
were produced as described [45] with the following 
modifications: pMD.G (#218) and pCMVDR8.91 (#219)
were replaced by pMD2.G and psPAX2 respectively.
Genome editing by CRISPR method
Single guide RNAs targeting the early exon 
of the protein of interest were chosen in the sgRNA 
library [46] and are listed in Table 2. LentiCRISPR 
plasmids specific for a gene were created according 
to the provided instructions. Oligos were designed as 
follow: Forward 5’-CACCGnnnnnnnnnnnnnnnnnn
nn-3’; Reverse-3’-CnnnnnnnnnnnnnnnnnnnnCAA-5’, 
where nnnnnnnnnnnnnnnnnnnn in the forward oligo 
corresponds to the 20 bp sgRNA. Oligos were synthetized, 
then phosphorylated and annealed to form oligo 
complexes. LentiCRISPR vector was BsmBI digested 
and dephosphorylated. Linearized vector was purified 
and gel extracted and ligated to oligo complexes. The 
lentiCRISPR vector containing the sgRNA was then used 
for lentivirus production. Cells were infected and selected 
with the appropriate dose of puromycin (2 µg/ml for Raji, 
1 µg/ml for NB1). Clone isolation was performed by 
limiting dilution in 96 well-plate.
TA cloning
TA cloning kit (Life technologies, ref. no. K202020) 
was used according to manufacturer’s instructions to 
sequence DNA fragment containing the region where Cas9 
was guided by a sgRNA.
Electron microscopy
NB1 cells were plated in poly-L-lysine (0.01%, 
Sigma-Aldrich, ref. no. P4832)-coated glass slides 
(LabTek Chamber Slides, ref. no. 177399) at a density 
of 300,000 cells per slide (area = 1.8 cm2), cultured 
for 24 hours. The Raji Burkitt lymphoma cells were 
cultured at a density of 200,000 cells per ml. The cells 
were treated as described in the figures. Cells were 
then fixed 2 hours in 2.5% glutaraldehyde (Electron 
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Microscopy Sciences, ref. no. 16220) dissolved in 
100 mM phosphate buffer (PB), pH7.4. After three 
washes in PB, cells were postfixed for 1 hour in 1% 
osmium tetroxide (Electron Microscopy Sciences, 
ref. no. 19150) in PB and then stained with ethanol 
70% containing 1% uranyl acetate (Sigma-Aldrich, 
ref. no. 73943) for 20 min. Raji and NB1 cells were 
dehydrated in graded alcohol series and embedded in 
epon (Electron Microscopy Sciences, ref. no. 13940). 
Ultrathin sections (with silver to gray interference) 
were cut with a diamond knife (Diatome), mounted 
on Formvar-coated single slot grids, and then 
counterstained with 3% uranyl acetate for 10 min and 
then with lead citrate (0.2%, Sigma-Aldrich, ref. no. 
15326) for 10 min. Sections were visualized using a 
Philips CM100 transmission electron microscope.
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